Search

everythinglearnresearchcommunity

for

Search:↓

Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.

The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.

The document concludes that hormone therapy is essential for treating gender dysphoria, with specific drugs and monitoring protocols recommended for safety and effectiveness.

Androgen therapy might help some women with low libido, but it has risks and should be used carefully.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Androgens are important for female fertility and could help in IVF treatment, but also play a role in causing PCOS.

Sex hormones affect reproduction, sexual development, and oral health, and it's important for dental practitioners to understand their effects and interactions.

DHEA may help with sexual function when used intravaginally by menopausal women but is similar to hormone therapy in other aspects and might cause more side effects like acne and hair loss.

Testosterone Replacement Therapy can improve sexual health in postmenopausal women with low sexual desire, but more research is needed on its long-term effects.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

A 5 mg dose of transdermal testosterone cream effectively restores testosterone levels in postmenopausal women.

Testosterone treatment can improve sexual function and bone density in women but may have adverse effects and requires more research on safety and guidelines.

Androgens play a role in female sexual function, and testosterone therapy can help women with low sexual desire, but more research is needed on treatments and long-term safety.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.

Australian doctors experienced in adult transgender healthcare mostly prescribe intramuscular testosterone and oral estradiol, recommend mental health assessments before hormone therapy, and support improved training and guidelines.

Androgen replacement therapy can improve libido and mood in women with severe androgen deficiency, but more research is needed on its long-term safety.

The conclusion is that published guidelines are improving transgender medical care, but more research and education in transgender medicine are needed.

Androgen conjugates might be better indicators of skin sensitivity to hormones in women with excessive hair growth.

Menopause often leads to lower sexual desire and discomfort during sex, but treatment should be personalized and only if it bothers the woman.

Testosterone therapy for postmenopausal women appears safe and may protect against heart disease, but requires constant monitoring and more research for long-term effects.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

Healthcare providers need better education and resources to give competent and sensitive care to transgender patients.

There are various effective hormone treatments for puberty induction in boys and girls with hypogonadism, and starting treatment early is important.

Ablative fractional resurfacing could improve how well topical drugs penetrate the skin, but more research is needed to fine-tune the method.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

Ethosomes are a promising way to deliver drugs through the skin.